Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Bird flu isn’t part of the “quad-demic” of viruses circulating through the country this winter—COVID, seasonal flu, respiratory syncytial virus (RSV ... of a bird flu vaccine.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

In November 2024, Moderna gained approval from Health Canada for its mRNA vaccine, mRESVIA, aimed at preventing lower ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024 ... This figure includes a mere $10 million in sales of the new RSV vaccine following its third-quarter launch, underscoring the ...